➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Express Scripts
Dow
Mallinckrodt
Harvard Business School

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Sotagliflozin


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Sotagliflozin?

Sotagliflozin is an investigational drug.

There have been 34 clinical trials for Sotagliflozin. The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Diabetes Mellitus, Type 1. The leading clinical trial sponsors are Sanofi, Lexicon Pharmaceuticals, and Juvenile Diabetes Research Foundation.

There are sixty US patents protecting this investigational drug and six hundred and seventy-five international patents.

Recent Clinical Trials for Sotagliflozin
TitleSponsorPhase
DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTanceUniversity of GlasgowPhase 3
DAPAgliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic RESISTanceNHS Greater Glasgow and ClydePhase 3
Dapagliflozin Plus Pioglitazone in T1DMThe University of Texas Health Science Center at San AntonioPhase 4

See all Sotagliflozin clinical trials

Clinical Trial Summary for Sotagliflozin

Top disease conditions for Sotagliflozin
Top clinical trial sponsors for Sotagliflozin

See all Sotagliflozin clinical trials

US Patents for Sotagliflozin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Sotagliflozin   Get Started Free Antidiabetic tricyclic compounds Merck Sharp & Dohme (Rahway, NJ)   Get Started Free
Sotagliflozin   Get Started Free [5,6]--fused bicyclic antidiabetic compounds Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Sotagliflozin   Get Started Free Factor XIa inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Sotagliflozin   Get Started Free [7,6]-fused bicyclic antidiabetic compounds Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
Sotagliflozin   Get Started Free Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Get Started Free
Sotagliflozin   Get Started Free Factor XIa inhibitors Merck Sharp & Dohme Corp. (Rahway, NJ)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Sotagliflozin

Drugname Country Document Number Estimated Expiration Related US Patent
Sotagliflozin Australia AU2015263620 2034-05-22   Get Started Free
Sotagliflozin Canada CA2947781 2034-05-22   Get Started Free
Sotagliflozin China CN106458913 2034-05-22   Get Started Free
Sotagliflozin European Patent Office EP3145915 2034-05-22   Get Started Free
Sotagliflozin Japan JP2017516771 2034-05-22   Get Started Free
Sotagliflozin South Korea KR20170005861 2034-05-22   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Express Scripts
Moodys
AstraZeneca
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.